【广东会GDH基因检测】监测未经治疗的非小细胞肺癌患者的循环肿瘤 DNA

基因检测要多少钱—答案

在高峰论坛中了解《Int J Mol Sci》在. 2022 Aug 23;23(17):9527.发表了一篇题目为《监测未经治疗的非小细胞肺癌患者的循环肿瘤 DNA》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Woo Kyung Ryu, Sekyung Oh, Jun Hyeok Lim, Seung Jae Lee, Hyun-Tae Shin, Jeong-Seon Ryu 等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

循环肿瘤DNA,监测,非小细胞肺癌

肿瘤靶向治疗基因检测临床应用结果

循环肿瘤 DNA (ctDNA) 已被用于监测接受靶向药物突变治疗的非小细胞肺癌 (NSCLC) 患者的临床过程。然而，尽管提供了关于 NSCLC 如何自然进展的宝贵信息，但 ctDNA 用于临床过程监测和预测没有可药物突变的初治 NSCLC 患者的临床效用仍然未知。我们通过收集临床信息、放射学数据和血浆样本，纵向跟踪了总共 12 名未接受过治疗的 NSCLC 患者，这些患者没有携带 EGFR 和 ALK 突变。相互比较了 ctDNA 水平和肿瘤负荷 (TB) 的变化。就诊断时的 ctDNA 检测分析了新的转移发展、体积倍增时间 (VDT) 和总生存期 (总生存期)。在 7 名 (58.3%) 患者的血浆中检测到 ctDNA。在相当大一部分（57.1%）患者中，ctDNA 水平的变化与结核病相关，并且还与其他患者的脑转移、肿瘤坏死或肺炎有关。所有进行 ctDNA 检测的患者在随访期间在诊断时没有转移的器官中都出现了新的转移。未检测到 ctDNA 的患者未发生新的转移（中位随访时间：9.8 个月）。此外，与未检测到 ctDNA 的患者相比，检测到 ctDNA 的患者 VDT 更短（p = 0.039），总生存期 更差（p = 0.019）。可以通过测量 ctDNA 水平来监测 NSCLC 进展的自然过程。诊断时检测ctDNA可以预测NSCLC患者新转移的发展、肿瘤快速生长和生存率低。监测；非小细胞肺癌。

肿瘤发生与反复转移国际数据库描述：

Circulating tumor DNA (ctDNA) has been utilized to monitor the clinical course of patients of non-small-cell lung cancer (NSCLC) who receive therapies targeting druggable mutations. However, despite providing valuable information on how NSCLC would naturally progress, the clinical utility of ctDNA for clinical-course monitoring and prediction of treatment-naïve NSCLC patients without druggable mutations remain unknown. We longitudinally followed a total of 12 treatment-naïve NSCLC patients, who did not harbor EGFR and ALK mutations, by collecting clinical information, radiological data, and plasma samples. Changes in ctDNA levels and tumor burden (TB) were compared with each other. New metastasis development, volume doubling time (VDT), and overall survival (OS) were analyzed regarding ctDNA detection at diagnosis. ctDNA was detected in the plasma of seven (58.3%) patients. Changes in ctDNA levels correlated with those in TB in a substantial fraction (57.1%) of patients and was also associated with brain metastasis, tumor necrosis, or pneumonia in other patients. All patients with ctDNA detection developed new metastasis during follow-ups in the organs that had been devoid of metastasis at diagnosis. The patients without ctDNA detection did not develop new metastasis (median duration of follow-ups: 9.8 months). In addition, patients with ctDNA detection had shorter VDT (p = 0.039) and worse OS (p = 0.019) than those without ctDNA detection. The natural course of NSCLC progression can be monitored by measuring ctDNA levels. Detection of ctDNA at diagnosis can predict development of new metastasis, rapid tumor growth and poor survival of NSCLC patients.Keywords: circulating tumor DNA; monitoring; non-small-cell lung cancer.